Table 1 Characteristics of patients with acute exposure vs. supra-therapeutic ingestions (RSTI)

Sociodemographic

Age (mean ± SD)

23.7 ± 14.6

40.3 ± 18.4

< 0.001

Gender (male)

3,276

2,950

< 0.001

Medical outcome

Major effect

320

813

< 0.001

Moderate effect

1,219

1,987

Minor effect

2,983

1,722

Gastrointestinal findings

AST, ALT levels >1000

401

1288

< 0.001

1000 > AST, ALT > 100

466

1,415

< 0.001

Increased bilirubin

114

422

< 0.001

Abdominal Pain

1,076

1,522

< 0.001

Nausea

2,048

1,825

< 0.001

Vomiting

2,349

1,577

< 0.001

LFT abnormality - other

108

275

< 0.001

Anorexia

6

34

< 0.001

Neurological findings

Confusion

64

135

< 0.001

Drowsiness/lethargy

334

182

< 0.001

Coma

45

37

0.22

Cardiovascular and respiratory findings

Hypotension

49

102

< 0.001

Conductance disturbance

22

12

0.08

Pulmonary edema

0

3

0.12

Coagulation findings

Prolonged PT/INR

282

748

< 0.001

Coagulopathy (other)

70

257

< 0.001

Cytopenia

4

32

< 0.001

Other bleeding

7

16

0.046

Renal findings

Oliguria/anuria

13

43

< 0.001

Renal failure

15

81

< 0.001

Creatinine increased

47

231

< 0.001

Dermatology findings

Erythema/flushing

15

45

< 0.001

Endocrinology findings

Hypoglycemia

10

37

< 0.001

Laboratory findings

Acidosis

97

238

< 0.001

Increased anion gap

69

97

0.017

Electrolyte abnormality

133

201

< 0.001

Miscellaneous findings

Diaphoresis

14

29

0.016

Fever/hyperthermia

8

19

0.026

NAC-IV

2,679

3,090

< 0.001

NAC-PO

427

522

0.003

Phytonadione

48

128

< 0.001